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Aims The prognostic value of coronary artery calcium (CAC) scoring is well established and has been suggested for use to
exclude significant coronary artery disease (CAD) for symptomatic individuals with CAD. Contrast-enhanced coronary
computed tomographic angiography (CCTA) is an alternativemodality that enables direct visualization of coronary sten-
osis severity, extent, and distribution. Whether CCTA findings of CAD add an incremental prognostic value over CAC
in symptomatic individuals has not been extensively studied.
Methods
and results
We prospectively identified symptomatic patients with suspected but without known CADwho underwent both CAC
and CCTA. Symptoms were defined by the presence of chest pain or dyspnoea, and pre-test likelihood of obstructive
CAD was assessed by the method of Diamond and Forrester (D–F). CAC was measured by the method of Agatston.
CCTAs were graded for obstructive CAD (.70% stenosis); and CAD plaque burden, distribution, and location.
Plaque burden was determined by a segment stenosis score (SSS), which reflects the number of coronary segments
with plaque, weighted for stenosis severity. Plaque distribution was established by a segment-involvement score (SIS),
which reflects the number of segments with plaque irrespective of stenosis severity. Finally, a modified Duke prognostic
index—accounting for stenosis severity, plaque distribution, and plaque location—was calculated. Nested Cox propor-
tional hazard models for a composite endpoint of all-cause mortality and non-fatal myocardial infarction (D/MI) were
employed to assess the incremental prognostic value of CCTA over CAC. A total of 8627 symptomatic patients
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(50%men, age 56+12 years) followed for 25months (interquartile range 17–40 months) comprised the study cohort.
By CAC, 4860 (56%) and 713 (8.3%) patients had no evident calcium or a score of .400, respectively. By CCTA, 4294
(49.8%) and 749 (8.7%) had normal coronary arteries or obstructive CAD, respectively. At follow-up, 150 patients
experienced D/MI. CAC improved discrimination beyond D–F and clinical variables (area under the receiver-operator
characteristic curve 0.781 vs. 0.788, P ¼ 0.004).When added sequentially to D–F, clinical variables, and CAC, all CCTA
measures of CAD improved discrimination of patients at risk for D/MI: obstructive CAD (0.82, P, 0.001), SSS
(0.81, P, 0.001), SIS (0.81, P ¼ 0.003), and Duke CAD prognostic index (0.82, P, 0.0001).
Conclusion In symptomatic patients with suspected CAD, CCTA adds incremental discriminatory power over CAC for discrimin-
ation of individuals at risk of death or MI.
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Introduction
Coronary artery calcium (CAC) scoring has been validated as a
robustmethod to effectively stratify the risk of future adverse cardio-
vascular events in asymptomatic patients in a manner incremental
to traditional clinical risk scoring and risk factors.1–3 An absent or
low coronary artery calcium is associated with a low risk of future
cardiac events in asymptomatic patients.
Recently, coronary computed tomographic angiography (CCTA)
has emerged as an accurate non-invasive method for the evaluation
of coronary artery disease (CAD) stenosis severity, extent, and dis-
tribution4–6 and has been shown to have a prognostic value in a
wide variety of patient settings.7 When examined in asymptomatic
patients, CCTA has not shown an incremental prognostic value
over CAC.8–10 In symptomatic patients, however, the incremental
prognostic utility of CCTA over CAC has not, to date, been exten-
sively examined. In a large internationalmultisite cohort of symptom-
atic individuals with suspected but without known CAD undergoing
both CAC and CCTA, we evaluated the prognostic utility of CCTA
findings of CAD over CAC.
Methods
Design
The rationale and design of CONFIRM (COronary CT Angiography
EvaluatioN For Clinical Outcomes: an InteRnational Multicenter
Registry) has been previously described.11 Briefly, CONFIRM is a multi-
center international, open-label, dynamic observational cohort study
that prospectively collects clinical, procedural, and follow-up data on
patients who underwent ≥64-detector row CCTA between 2003 and
2009. The study herein represents consecutive symptomatic patients
enrolled at 12 centres in six countries (Canada, Germany, Italy, Korea,
Switzerland, and USA).
Patients
A total of 27 125 patients comprise the CONFIRM cohort, of which
8627 met the inclusion criteria for the present study (Figure 1). Adult
patients were included if they were symptomatic with suspected but
without known CAD who were followed for the composite endpoint
of all-causemortality and non-fatal myocardial infarction (MI). Symptoms
suspicious of CAD were defined by the presence of chest pain or dys-
pnoea. Patients were excluded if they were asymptomatic (n ¼ 7590),
did not undergo CAC with the CCTA (n ¼ 7157), had known prior
CAD (n ¼ 2850), patients with missing variables (including those with
poor image quality) (n ¼ 835), or lost to follow-up (n ¼ 66). Baseline
characteristics and demographics as well as data necessary to calculate
the Diamond–Forrester score (D–F)12 were obtained by direct inter-
view of the patients at each site by a physician or nurse coordinator,
with D–F was calculated for every patient. The study protocol was
approved by the Institutional Review Boards and/or Ethics Committees
of each site.
Data acquisition and image analysis
Image datawere acquired byCT scanners of≥64-detector rows. Patient
preparation, acquisition, and interpretation of CCTA and CAC data as
well as clinical results were performed in accordance with the Society
of Cardiovascular Computed Tomography guidelines by board certified
cardiovascular CTand/or level III equivalent experts.13CAC scoreswere
measured based on the scoring system described by Agatston et al.14
CAC were categorized into four groups; as 0, 1–99, 100–399, and
≥400. CCTAs were interpreted on a per-patient, per-vessel, and
per-segment basis, with a 15-segment coronary artery tree model
employed [left main; proximal, mid, and distal left anterior descending
(LAD)artery; first and seconddiagonal branchesof theLADartery; prox-
imal and distal left circumflex (LCx) artery; first and second obtuse
marginal branches of the LCx artery; proximal, mid, and distal right cor-
onary artery; posterior descending artery; and posterolateral branch
(left or right)]. In addition, coronary artery plaque scoreswere calculated
for overall plaque burden by the extent and severity of CAD using a
segment stenosis score (SSS) and segment-involvement score (SIS). SSS
was used as a measure of coronary plaque burden. Each individual
segment was scored from 0 to 3 (normal to severe) luminal obstruction.
After this, scores of all 15 individual segmentswere summed to give a total
score ranging from 0 to 45. CADwas defined as the presence of any cor-
onary plaque. As a measure of CAD distribution, the SIS was calculated
based on just the presence of plaque within a segment, irrespective of
the degree of luminal stenosis within each segment (minimum ¼ 0;
maximum¼ 15).15 Further, a modified Duke CAD index—combining
the location, extent, and severity of coronary stenoses—was determined
in a manner that provides incremental and linear gradations of prognostic
risk of incident death in relations to the extent and severity of CAD.15,16
Within the Duke CAD index, eight groups were considered: Group 0 ¼
no CAD; Group 1 ¼ ≥1 segment with 1–49% stenosis; Group 2 ¼ ≥2
segmentswith1–49%stenosis andat≥1proximal segmentwithanysten-
osis; Group 3 ¼ ≥1 segment with 50–69% stenosis; Group 4 ¼ ≥2 seg-
ments with 50–69% stenosis or≥1 segment with ≥70% stenosis; Group
5 ¼ ≥3 segments with 50–69% stenosis or ≥2 segments with ≥70%
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stenosis or pLAD with ≥70% stenosis; Group 6 ¼ ≥3 segments with
≥70% stenosis or ≥2 segments with ≥70% stenosis and pLAD with
≥70% stenosis; Group 7 ¼ left main with ≥50% stenosis. Based on
these gradations and their associated prognosis, patients were also cate-
gorized into two separate groups that included non-high-risk CAD
(Groups 0–4) and high-risk CAD (Groups 5–7).
In each coronary artery, coronary atherosclerosis was defined as any
tissue structures of .1 mm2 that existed either within the coronary
artery lumen or adjacent to the coronary artery lumen that could be dis-
criminated from surrounding pericardial tissue, epicardial fat, or the
vessel lumen itself. Coronary atherosclerotic lesions were quantified
for stenosis by visual estimation. Coronary artery plaque was quantified
on both per-patient assessment: visual estimation of the stenosis into
four categories; none (0% stenosis), mild (1–49% stenosis), moderate
(50–69% stenosis), and severe (≥70% stenosis). CAD was defined as
the presence of any plaque. Obstructive CAD was defined as ≥50%
luminal stenosis.
Patient follow-up and events
The primary endpoint was a composite of death or non-fatal MI, with
follow-up occurring for a median duration of 25 months (interquartile
range 17–40 months). Data required for death was obtained by the
national death index in US sites while direct interview, telephonic en-
counter, or review of medical records was performed within non-US
sites. MI was defined as per the universal definition of MI.17 Ascertain-
ment of MI was obtained by direct interview, telephone calls, and/or
medical record review at all sites.
Statistical analysis
Continuous variables are expressed as means+ standard deviation,
whereas categorical variables are presented as absolute values and
percentages. Group comparisons were carried using the x2 test or
Fisher’s exact test for categorical variables and Student’s’ t-test for
continuous variables. Kaplan–Meier analysis was used for survival
analysis, and the different CAC and CCTA groups were compared
with the log—rank test. Multiple nested Cox proportional hazard
models were used to determine the incremental prognostic value
of CCTA over CAC, and pre-test likelihood as determined by D–F
analysis. The predicted risk was calculated for each model, and the
area under the curve (C-index) was calculated for each model in
order to discriminate individuals at risk of the composite endpoint.
We further performed secondary analyses restricted to patients
with any evidence of atherosclerosis by CAC, as well as those with
CACof.10Agatston units. The latter of thesewas chosen for a clin-
ically meaningful cut-off with a sufficient number of clinical events
(n ¼ 115) to provide adequate statistical power (b. 0.80). The
P-value under 0.05 was considered statistically significant, and all
analyses were performed with STATA version 11.
Results
Study cohort
The characteristics of the patients in the study cohort are summar-
ized in Table 1. Atypical chest pain was the most frequently reported
symptom (66.1%). Of the study population, 25, 65, and 10% of the
patient population were considered the low, intermediate, and high
pre-test likelihood of CAD by D–F classification. Patients with ob-
structive or non-obstructive CAD were older and more often
male, with a higher prevalence of hypertension, diabetes, current
smoking, and dyslipidaemia (Table 1).
Coronary artery calcium
Coronarycalcificationwasdetected in3766 (43.7%)patients.Among
patients with detectable calcium, the mean CACwas 260+485 and
the median CAC was 78 (25–75th, interquartile range 16–286).
A total of 730 (8.5%), 1333 (15.5%), 990 (11.1%), and 713 (8.3%)
patients had CACof 1–9, 10–99, 100–399, and ≥400, respectively.
CAD by CCTA
EvidenceofCADbyCCTAwaspresent in 4294 (49.8%) patients, and
obstructive CAD was present in 749 (8.7%) patients. Higher CAC
was associated with a greater extent of CAD (P, 0.001). The
mean SIS and SSS were 1.74+2.58 and 2.29+ 3.89, respectively.
Using the Duke CAD classification, 618 (8%) patients had high-risk
anatomy.
Follow-up and outcomes
After a median follow-up of 25 months, 95 patients died and 64
experienced MI (9 fatal and 55 non-fatal). The composite outcome
composed of non-fatal MI or death occurred in 150 patients.
A graded increase in the risk of death or non-fatal MI existed with in-
creasing CAC (Figure 2) and the presence of obstructive CAD by
CCTA (Figure 3). Among patients with a zero calcium score,
plaques were detected in 828 patients. There was a trend towards
an increased event rate among patients with plaques and zero
calcium score (P ¼ 0.07) (Figure 4). In every CAC group, there was
a graded increased in the annual event rate with the presence of
non-obstructive CAD and obstructive CAD on CCTA (Figure 5).
By univariate analysis, increased hazards for death or non-fatal MI
were observed with increasing CAC (P, 0.0001 for trend), with
higher rates of events for individuals with CAC scores between
10–99, 100–399, and .400 when compared with individuals with
no evident calcium (Table 2). Among 4860 patients with a zero
Figure 1: Prevalence of obstructive and non-obstructive CAD
among the study population.
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calcium score, only 66 (1.36%) patients had evidence of obstructive
CAD and 31 events occurred in these patients (annual event rate
of 0.30%), of whom 22 had normal-appearing CCTA (annual event
rate of 0.24%); 9 events (21 death and 10 MI) occurred in patients
with zero CAC and CAD by CCTA. On CCTA, multiple measures
of CAD were associated with increased hazards for death or MI,
with the presence of obstructive CAD showing with an eight-fold in-
crease in risk of death or MI (hazards ratio [HR] 8.2, 95% confidence
interval [95%CI] 5.9–11.4). Similarly, CCTA scoresmeasuring CAD
extent and distribution were associated with greater risk of adverse
eventsby the SSS (HR1.15per stenosed segment, 95%CI1.13–1.17)
and SIS (HR 1.31 per-segment involved, 95% CI 1.25–1.36).
Multivariable Coxmodels of CAC
and CCTA
In multivariable models accounting for clinical risk factors including
age, gender, hypertension, diabetes, dyslipidaemia, and current
smoking, CACS of .400 (HR 4.8; 95% CI 2.9–8.1; P ≤ 0.0001)
was significantly associated with future death or MI. CCTA models
were predictive of adverse outcomes by the presence, extent, and
distribution of CAD (P, 0.05 for all; Table 2). The presence of any
obstructive CAD was independently associated with increased risk
of D/MI (HR 3.9; 95% CI 2.7–5.5). In addition, measures of the
Figure 3: Presence of coronary plaques and events in the study
population. The curves demonstrate a graded risk of death or MI
by the presence of both plaques in patients with a zero calcium
score and non-zero calcium score (trend P, 0.0001).
Figure 2: Relation between CAC and composite endpoint of
death or non-fatal MI, demonstrating a graded risk with increasing
CAC (P, 0.0001).
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Table 1 Baseline characteristics
Variables Total Obstructive
CAD >70%
Non-obstructive
CAD
No CAD Trend
P-value
N 8627 749 (8.7%) 3584 (41.5%) 4294 (49.8%)
Age (years) 56.5+12 62.8+10.4 60.1+10.6 51.9+11.6 ,0.001
Gender (female %) 50% 236 1596 2483 ,0.001
Diabetes mellitus, n (%) 1139 (13.2%) 168 (22%) 595 (16.6%) 376 (8.7%) ,0.001
Dyslipidaemia, n (%) 4847 (56.2%) 528 (69%) 2206 (61%) 2113 (50%) ,0.001
Hypertension, n (%) 4346 (50.4%) 516 (67%) 2038 (57%) 1792 (42%) ,0.001
Current smoking, n (%) 1464 (17.0%) 205 (24%) 600 (16%) 659 (16%) ,0.001
Family history of premature CAD, n (%) 2487 (28.8%) 321 (39%) 1055 (29%) 1111 (27%) ,0.001
Pre-test likelihood
Low 4226 (49%) 247 (33%) 1720 (48%) 2259 (60%) ,0.001
Intermediate 3623 (42%) 337 (45%) 1578 (44%) 1708 (36%)
High 778 (9%) 165 (22%) 286 (8%) 327 (4%)
BMI (kg/m2) 27.5+5.3 28.0+5.1 28+5.5 26.9+5.3 ,0.001
Calcium score ≥400, n (%) 714 (9%) 317 (42%) 397 (11%) 0 ,0.001
Zero calcium score, n (%) 4860 (56%) 66 (9%) 764 (16%) 4030 (75%) ,0.001
CAD, coronary artery disease; BMI, body mass index.
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extent of CAD were predictive of D/MI including the presence of
left main disease (HR 1.7; 95% CI 1.2–2.4), SSS (HR 1.09; 95% CI
1.07–1.10), and SIS (HR 1.18; 95% CI 1.13–1.24).
Incremental value of CAC and CCTA
for the prediction of future death or MI
CAC and CCTA alone demonstrated improved discrimination over
clinical risk factors for individuals at risk for futuredeathorMI. Table 3
lists the C-statistics for the prediction of death or MI using multiple
models of D–F, clinical variables, CAC, and CCTA findings. The
addition of CAC resulted in improved discrimination compared
with D–F and clinical variables alone. Obstructive CAD by CCTA
increased the C-index over models containing CAC (HR 0.779,
95% CI 0.737–0.820). Similarly, the addition of SSS or SIS also
increased C-statistics compared with D–F and clinical factors
alone, evenwhen combined with CAC (P, 0.001 for all). For indivi-
duals classified as intermediate-to-high risk for CADbyD–F classifi-
cation (n ¼ 3744), CCTA also improved the C-index (from 0.765 to
0.810, P ¼ 0.01).When restricted to only individuals with detectable
calcium by CAC, CCTA findings continued to add an incremental
prognostic value (Table 3). When only patients with a calcium score
of .10 were included (3054 patients and 115 events), obstructive
CAD by CCTA similarly added an incremental value over CAC
(C-index 0.727 0.769, P ¼ 0.01). However, this incremental value
was reduced to a trend when only patients with a calcium score of
.100 were included (1600 patients and 79 events; C-index 0.749
0.714, P ¼ 0.10). Among patients with CCS of .400, CCTA did not
add incremental value over CCS (C-index 0.674 0.841, P ¼ 0.55).
Discussion
In this largemulticenter international cohort of symptomatic patients
without known CAD, the present data demonstrate that findings
of extent, severity, and distribution of CAD by CCTA add an incre-
mental discriminatory value to identify individuals at risk of death
or MI over models incorporating clinical CAD risk factors, D–F
pre-test likelihood of CAD and CAC.
Chest pain and dyspnoea are common presentations for symp-
tomatic individuals with suspected CAD in the primary care office
and cardiology practice. Current ACC/AHA guidelines for the man-
agement of patients with stable angina endorse the use of exercise
ECG, stress echocardiography, and myocardial perfusion imaging as
acceptablemodalities for the evaluation of these patients, dependent
on the pre-test likelihood of CAD.18
CAC and CCTA are alternative anatomic imaging modalities that
have been espoused for diagnosis and prognosis of individuals with
suspected CAD. However, findings regarding the use of CAC in
symptomatic patients for assessing the extent and severity of CAD
and prognosis have been inconsistent.19 Employing electron beam
CT to quantify CAC in symptomatic individuals with suspected
CAD, Schmermund et al.20 found that calcium scanning in conjunc-
tion with CAD risk factor profiles was useful to identify or exclude
invasive angiographically severe disease, defined as three-vessel
and/or left main CAD. In other studies, CAC correlated with ischae-
mic defects by functional stress testing and offered complementary
information for the prediction of short- and long-term cardiac
events.21,22 In contrast, Gottlieb et al.23 showed that, in symptomatic
patients referred for conventional coronary angiography, the
absence of coronary calcification does not exclude obstructive
CAD or the need for revascularization. In a recent systematic
review of the use of CAC in symtomatic patients, the presence of
anyCACresulted in a high sensitivity (range70–100%), but relatively
low specificity for predicting the presence of obstructive coronary
disease among symptomatic patients subsequently referred for
coronary angiography. Conversely, a CAC score of 0 in low- and
intermediate-risk emergency department populations with chest
pain imparted a high negative predictive value (99.4%) for events
over an average follow-up of 21 months.24
Figure 4: Interaction between calcium score, obstructive (obs)
CADonCCTAandevents in the studypopulation.Thecurvesdem-
onstrate a graded risk of death or MI by both the presence of
obstructive CAD in patients with a zero calcium score and the
presence of both non-obstructive and obstructive CAD (trend
P, 0.0001).
Figure 5: Annual event rates across the spectrum of calcium
score. In every calcium score group, there was a graded increase
in the annual event rate with the presence of non-obstructive and
obstructive CAD on CCTA (all P, 0.05).
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To date, evidence regarding the utility of CCTA beyond CAC in
symptomatic individuals with suspected CAD is limited. In this
patient population, CCTA has an excellent diagnostic accuracy to
rule out or confirm CAD.5 In addition, it can detect obstructive
CAD even in patients with a zero or low calcium score.19 Our
study findings provide a clear signal that, in this symptomatic
individuals, CCTA adds an incremental value over CAC for discrim-
ination of future death of MI, particularly in patients withCAC scores
not severely elevated. Multiple measures of extent, severity, and dis-
tribution of CAD by CCTA were evaluated, and each consistently
offered prognostic utility beyond CAC. Importantly, in models in-
corporating CAD risk factors, D–F pre-test likelihood and CAC,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 C-statistics for prediction of 25 months risk of all-cause mortality and non-fatal MI using combined models
Model C-statistic 95% CI P-value
Compared with
Model II
(DF1 clinical)
Compared with
Model III (DF1
clinical1 CAC)
Entire cohort
Model I: DF 0.554 0.502–0.605 – –
Model II: DF + clinicala 0.781 0.740–0.822 ,0.001* –
Model III: DF + clinical + CAC 0.788 0.747–0.829 0.004 –
Model IV: DF + clinical + CAC + obstructive CAD 0.817 0.777–0.856 ,0.001 0.002
Model V: DF + clinical + CAC + Duke index 0.821 0.784–0.859 ,0.001 ,0.001
Model VI: DF + clinical + CAC + SSS 0.814 0.775–0.853 ,0.001 ,0.001
Model VII: DF + clinical + CAC + SIS 0.808 0.770–0.847 0.003 0.004
Patients with detectable coronary calcium
Model I: DF 0.521 0.464–0.578 –
Model II: DF + clinical 0.738 0.689–0.786 ,0.001* –
Model III: DF + clinical + CAC 0.741 0.695–0.793 0.044 –
Model IV: F DF + clinical + CAC + obstructive CAD 0.786 0.741–0.830 0.002 0.007
Model V: DF + clinical + CAC + Duke index 0.789 0.747–0.832 ,0.001 ,0.001
Model VI: DF + clinical + CAC + SSS 0.778 0.734–0.825 ,0.001 0.002
Model VII: DF + clinical + CAC + SIS 0.769 0.723–0.814 0.018 0.044
DF, Diamond Forrester score; CAC, coronary artery calcium score; CAD, coronary artery disease; SIS, segment-involvement score; SSS, segment severity score.
aClinical model includes age, gender, hypertension, diabetes, dyslipidaemia, and current smoking.
*P-value compared with DF alone.
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Table 2 CAC and coronary CCTA predictors of death and MI
Variables Univariate HR Age and gender
adjusted HR
Age, gender and risk
factorsa adjusted HR
Calcium score
≥400 13 (8.2–20.6) 6.1 (3.6–6.7) 4.8 (2.9–8.1)
100–399 7.3 (4.5–11.9) 4 (2.4–6.7) 3.6 (2.1–6.0)
10–99 3.9 (2.3–6.6) 2.5 (1.5–4.3) 2.3 (1.3–3.9)
1–9 1.2 (0.5–3.1) 0.9 (0.3–2.3) 0.8 (0.3–2.3)
0 Reference Reference Reference
Coronary CT angiography
Any severe stenosis 8.2 (5.9–11.4) 4.8 (3.4–6.8) 3.9 (2.7–5.5)
Obstructive left main CAD 3.6 (2.5–5.0) 1.9 (1.3–2.7) 1.7 (1.19–2.25)
Number of vessels with obstructive CAD (per vessel) 1.75 (1.29–2.37) 1.70 (1.24–2.33) 1.64 (0.94–1.13)
Segment stenosis score (per-segment involved) 1.15 (1.13–1.17) 1.11 (1.08–1.13) 1.09 (1.07–1.10)
Segment-involvement score (per-segment involved) 1.31 (1.25–1.36) 1.21 (1.16–1.27) 1.18 (1.13–1.24)
CAD, coronary artery disease; HR, hazard ratio.
aRisk factors include hypertension, diabetes, dyslipidaemia and current smoking.
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measures of obstructive coronary stenosis among epicardial cor-
onary arteries were effective at discriminating future hazards of
death and MI, suggesting that identification of angiographically
severeCADbyCCTA is useful for defining risk. Further, employing
amultitudeof additionalCADmeasures—including extent and dis-
tribution—the incremental discriminatory value of CCTA over
CAC persisted, suggesting that overall coronary plaque burden
beyond calcified plaque alone are useful for prognosticating
adverse outcomes, especially in patients with a calcium score of
1–100.
Weobserveda lowadverse event rate among individualswithCAC
of 0, a finding in direct accordancewith other prior studies for asymp-
tomatic and symptomatic individuals undergoing CAD evaluation.
Prior studies have evaluated the rates of angiographically severe sten-
osis for individuals with CAC of 0—primarily in low-risk individuals
presenting with acute symptoms—and have observed a non-
negligible rate of obstructive stenosis between 2 and 19%.8,23,25
In our cohort, only 1.36% of symptomatic patients with a zero
calcium score had evidence of obstructive CAD and suggests CAC
as a potentially useful ‘gatekeeper’ to further angiographic testing.
CCTA has the advantage of visualizing the non-calcified plaque in
these patients, an advantage over CAC. However, it remains
unclear when one should proceed to CCTA in all symptomatic
patients with a zero calcium score. Prior literature suggests that
high pre-test likelihood or high Framingham risk score are associated
with increased odds for the presence of non-calcified obstructive
plaque.26
WhileCCTA is anexcellent non-invasive tool for the identification
of anatomical CAD severity, it does not discriminatewhether a sten-
osis causes ischaemiaornot. Recently, newCT-based tools areunder
investigation to determine whether CCTA measures of functional
flow reserve or CT perfusion may be able to differentiate between
lesions that are associated with ischaemia or not. In our analysis,
the ischaemic burden associated with CCTA lesions was not
accounted for in our models due to the lack of functional data in
our registry.
Our analysis is in agreement in prior single-centre studies that
addressed the same question in a smaller cohorts.27,28 In a single-
centre study, Hou and colleagues followed 5007 outpatients with
suspected CAD for a median period of 1081 days. At the end of
the follow-up period, 363 (8.2%) patients experienced major
adverse cardiac events. In multivariate analysis, the area under the
receiver-operating characteristic curves increased from0.71 for clin-
ical risk factors to 0.82 by adding CAC and further improved to 0.93
byaddingCCTA.However, thepresent studyfindings are in apparent
discordance with a previous report by our group that observed no
added prognostic benefit of CCTA over CAC in asymptomatic indi-
viduals.10 Yet the population studied differs greatly from the prior
investigation in that the present study restricted analysis of the prog-
nostic utility of CCTA findings solely to symptomatic stable indivi-
duals only. In this cohort, we noted that the extent, severity, and
distribution of CAD added an incremental value of CAC alone.29
This was mostly seen primarily among patients with a calcium score
of ,100 and suggests that the utility of CCTA may be greatest in
those with ‘moderate’ CAC scores. This finding is not unanticipated,
given the remarkably poor prognosis associated with higher CAC
scores (e.g. .400). We also noted that the event rate is high in the
presence of extensive coronary atherosclerosis when determined
by either CAC scanning or CTA.
Study strengths and limitations
Our study has the advantage of beingmulticenter and international in
design—features which increase the generalizability of the present
findings. Nevertheless, although prospective in nature, these obser-
vational data are not immune to the limitations of any observational
registry, including referral and selection bias. The follow-up duration
was short (median25months).Wepurposelyemployed acomposite
outcomeof all-causemortality andnon-fatalMIs, given the ‘hard’ end-
point nature of both of these conditions. However, we did not have
cause specific death in our registry. Finally, we did not evaluate the
incremental value of CCTA in models that incorporate CAC and
functional stress testing findings, the latter of which is recommended
for use for symptomatic individuals with suspected CAD, but was
lacking in the present study.
Conclusion
Incremental to D–F pre-test likelihood, CAD risk factors, and CAC,
CCTA improves discrimination of symptomatic individuals at risk of
death or MI.
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